Published on November 28, 2023, 9:42 am
Dutch biotech startup Cradle is making waves in the field of protein engineering with its pioneering use of generative artificial intelligence (AI). With a substantial investment of $24 million, the company aims to revolutionize protein design and engineering.
Cradle’s focus lies in using generative AI to go beyond traditional forms of proteins. Their ongoing projects involve engineering diverse protein sequences and three-dimensional structures, with potential applications in enzyme production, vaccine development, lab-grown food, and material sciences.
Generative AI has the power to transform biotechnology by using algorithms to generate new data through pattern recognition in existing datasets. This technology has proven particularly useful in drug discovery, protein engineering, diagnostics, and personalized medicine solutions.
Cradle takes a unique approach by treating human protein amino acid sequences as a programming language. This perspective has led them to integrate AI models into their work. While generative AI cannot currently create proteins with specific functions, it enables scientists to identify and select proteins suited for different conditions such as room temperature stability or acidity.
One of Cradle’s major strengths is its proprietary AI, which has been trained on billions of protein sequences and in-house laboratory data. This game-changing technology assists biologists in designing superior proteins, accelerating research and development processes, and expediting drug development. Additionally, Cradle offers web-based software solutions for other companies to leverage their data for generative AI and machine learning tools.
The recent Series A investment round saw contributions from prominent investors like Index Ventures, Kindred Capital, as well as individual investors. This funding brings Cradle’s total raised capital to $33 million. Since its establishment in 2021 by a former Google AI Senior Product Manager, the company has already secured partnerships with industry giants such as Johnson & Johnson, Novozymes A/S, and Twist Bioscience.
Cradle is not alone in its pursuit; Evozyne is another deep learning biotech startup that recently closed an $81 million Series B funding round. Evozyne focuses on AI-driven drug development, relying on algorithms that simulate protein evolution more efficiently than traditional methods.
The integration of AI into biotech is a booming trend with no signs of slowing down. As companies like Cradle and Evozyne continue to innovate, the potential for groundbreaking discoveries and advancements in the field of protein engineering and AI-driven biotechnology becomes increasingly promising.
Cradle’s recent investment marks a significant milestone in the application of generative AI in biotechnology. With their innovative approach and the support of influential investors, Cradle is poised to lead the way in shaping the evolving landscape of protein engineering and AI-driven biotechnology.